ArticleBMC health services research2026
Multidimensional evaluation of the potential impact of faricimab availability on healthcare system accessibility for retinal disease treatment in Poland.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate the impact of introducing faricimab into a publicly funded drug programme for retinal diseases, focusing particularly on reducing treatment frequency and optimising resources. Faricimab, a bispecific antibody targeting angiopoietin-2 and VEGF-A, offers a dual mechanism for managing nAMD and DME, both leading causes of vision loss.
methodsThe analysis included forecasting patient treatment trends, estimating the potential market share of faricimab, and simulating drug administration frequencies. A Monte Carlo simulation was conducted to model the impact of faricimab on reducing injection frequency. Scenarios with variable patient numbers and administration rates were explored, covering the years 2025, 2030, and 2035, to assess potential efficiencies in healthcare resources use and the capacity to treat additional patients.
resultsResults indicated that faricimab could reduce injection frequency by approximately 15%, freeing up resources within the healthcare system. Under the primary scenario, faricimab introduction could enable an additional 2,115 patients to be treated in 2025, rising to 7,662 by 2035 without additional resources. In the minimum scenario, the capacity increased by 4,415 patients by 2035, while the maximum scenario saw an increase of 12,003 patients.
conclusionsThe introduction of faricimab is expected to improve access to ophthalmic treatments, especially within the drug programme for retinal diseases, by decreasing injection frequency and enhancing resource efficiency. Given Poland’s ageing population and the rising prevalence of nAMD and DME, faricimab adoption could alleviate pressures on healthcare infrastructure, ultimately supporting better patient outcomes and overcoming current limitations in access to ophthalmic services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.